Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: Hong-Lee Yu who wrote (778)	8/25/1998 9:51:00 PM
From: FNS	Read Replies (1) \| Respond to of 965

Hong-Lee: <<Most people forgot Retavase acquisition takes out about 40-50C in 1998 earning and 20C in 1999 earning.>> Agreed, but Retavase was to be a creative deal...I need to do some digging to see if th Retavase earning's impact is going as projected. Where does the lawsuit on this all stand??? Have been out of the country 5 weeks and still trying to catch up! Regarding Reopro production cost and profit margin, does anybody know if CNTO management is addressing this? With increased sales projections, it would be nice if CNTO could cut production cost of REOPRO and still maintain a good profit margin. CNTO better start looking at this cause I'm sure IMNX and CORR have no choice but to cut costs of their respective drugs to compete successfully! And we can soon expect CYPB to get FDA approval. Thanks for your input. FNS